abstract |
Disclosed herein is a pyrrolidine compound as given, wherein n is an integer from 1 to 4, M is CR1R2, q1 is 0, q2 is 1, and the other substituents are as defined within the specification. Also disclosed are processes for their preparation, compositions comprising said compounds and use of the compounds in the treatment of a disease associated with aberrant leukocyte recruitment, activation or recruitment and activation. |